Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Le Gouill S, Ghesquieres H, Oberic L, Morschhauser F, et al. Blood 2021;137:2307-2320.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Le Gouill S, Ghesquieres H, Oberic L, Morschhauser F, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood 2021;137:2307-2320.
PMID: 33211799